v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by the CODM are reported on the condensed consolidated statements of earnings for the periods ended June 30, 2026 and 2025. The CODM uses net earnings as its principal measure of segment profit or loss to compare past financial performance with current performance and analyze underlying business performance and trends. The CODM does not use segment assets to make decisions regarding resources; therefore, the total asset disclosure has not been included.
The following table details AbbVie’s worldwide net revenues:
Three months ended
June 30,		Six months ended
June 30,
(in millions)2026202520262025
Immunology
SkyriziUnited States$4,767 $3,843 $8,542 $6,762 
International738 580 1,446 1,086 
Total$5,505 $4,423 $9,988 $7,848 
RinvoqUnited States$1,765 $1,452 $3,170 $2,672 
International760 576 1,474 1,074 
Total$2,525 $2,028 $4,644 $3,746 
HumiraUnited States$425 $802 $782 $1,546 
International331 378 662 755 
Total$756 $1,180 $1,444 $2,301 
Neuroscience
VraylarUnited States$1,068 $898 $1,970 $1,661 
International3 2 6 4 
Total$1,071 $900 $1,976 $1,665 
Botox TherapeuticUnited States$864 $775 $1,706 $1,498 
International178 153 345 296 
Total$1,042 $928 $2,051 $1,794 
UbrelvyUnited States$379 $330 $709 $563 
International13 8 22 15 
Total$392 $338 $731 $578 
QuliptaUnited States$289 $237 $539 $409 
International61 30 107 51 
Total$350 $267 $646 $460 
VyalevUnited States$128 $22 $217 $28 
International128 76 240 133 
Total$256 $98 $457 $161 
Other NeuroscienceUnited States$43 $71 $89 $146 
International74 81 153 161 
Total$117 $152 $242 $307 
Oncology
VenclextaUnited States$369 $321 $710 $633 
International402 370 831 723 
Total$771 $691 $1,541 $1,356 
Three months ended
June 30,		Six months ended
June 30,
(in millions)2026202520262025
ImbruvicaUnited States$337 $543 $669 $1,072 
Collaboration revenues195 211 419 420 
Total$532 $754 $1,088 $1,492 
Elahere
United States
$161 $138 $321 $303 
International
50 21 88 35 
Total$211 $159 $409 $338 
Epkinly
Collaboration revenues
$64 $49 $115 $85 
International39 21 71 36 
Total$103 $70 $186 $121 
Other OncologyUnited States$33 $2 $57 $2 
Aesthetics
Botox CosmeticUnited States$400 $410 $771 $705 
International328 282 625 543 
Total$728 $692 $1,396 $1,248 
Juvederm CollectionUnited States$103 $105 $188 $180 
International142 155 289 311 
Total$245 $260 $477 $491 
Other AestheticsUnited States$258 $282 $506 $552 
International51 45 89 90 
Total$309 $327 $595 $642 
Other Key Products
MavyretUnited States$133 $184 $316 $326 
International162 191 330 355 
Total$295 $375 $646 $681 
CreonUnited States$345 $404 $706 $759 
Linzess
United States$283 $247 $555 $386 
International12 11 23 20 
Total$295 $258 $578 $406 
All other$1,109 $1,117 $2,134 $2,370 
Total net revenues$16,990 $15,423 $31,992 $28,766 
See the following for additional information about certain income and expenses included in net earnings: intangible assets amortization expense (Note 6), change in fair value of contingent consideration (Note 7), interest income and expense (Note 2), depreciation expense (Note 2), litigation matters (Note 11) and income tax expense (Note 10).